FOLH1 and nonpapillary renal cell carcinoma: A general clinical relevance of PSMA-PET/CT can be assumed, since a retrospective evaluation of Ga-68-PSMA-PET/CT examinations in RCC patients showed that PET/CT directly changed management in 42% of cases, 87.5% of PET-positive patients had ccRCC and one of eight ccRCC was PET-negative [18].